Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) have earned an average recommendation of “Hold” from the four analysts that are presently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is $1.00.
INFI has been the subject of several recent research reports. ValuEngine downgraded Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research downgraded Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Price Target at $1.00” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/19/infinity-pharmaceuticals-inc-nasdaqinfi-given-average-recommendation-of-hold-by-brokerages-updated-updated.html.
Hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. bought a new stake in shares of Infinity Pharmaceuticals during the second quarter worth about $130,000. Legal & General Group Plc boosted its stake in shares of Infinity Pharmaceuticals by 2,430.0% in the second quarter. Legal & General Group Plc now owns 349,346 shares of the biotechnology company’s stock worth $548,000 after buying an additional 335,538 shares during the period. LMR Partners LLP bought a new stake in shares of Infinity Pharmaceuticals during the second quarter worth about $222,000. Platinum Investment Management Ltd. boosted its stake in shares of Infinity Pharmaceuticals by 62.6% in the first quarter. Platinum Investment Management Ltd. now owns 810,232 shares of the biotechnology company’s stock worth $2,617,000 after buying an additional 312,000 shares during the period. Finally, Highbridge Capital Management LLC bought a new stake in shares of Infinity Pharmaceuticals during the first quarter worth about $106,000. 75.22% of the stock is currently owned by institutional investors and hedge funds.
Shares of Infinity Pharmaceuticals (NASDAQ INFI) traded up 1.71% during trading on Tuesday, hitting $1.19. 357,326 shares of the stock traded hands. The firm’s market cap is $60.32 million. Infinity Pharmaceuticals has a 52 week low of $0.84 and a 52 week high of $3.84. The company has a 50-day moving average of $1.46 and a 200-day moving average of $2.09.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by $0.12. During the same period last year, the company posted $1.05 earnings per share. On average, analysts forecast that Infinity Pharmaceuticals will post ($0.89) EPS for the current fiscal year.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
What are top analysts saying about Infinity Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Infinity Pharmaceuticals Inc. and related companies.